Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis Clinical Trial

Official title:

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03368339
• Other study ID #: 17-100-0007
• Status: Completed
• Phase: Phase 2
• Start date: December 10, 2017
• Est. completion date: January 28, 2018

Study information

• Verified date: August 2019
• Source: Realm Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).

Description:

A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of PR013 Topical Ophthalmic Drops (0.045% and 0.06%) Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CAC®)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: January 28, 2018
• Est. primary completion date: January 21, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

• be at least 10 years of age of either sex and any race

• have a positive history of ocular allergies and a positive skin test reaction to a perennial allergen (cat dander, dog dander, dust mites, cockroaches) and a seasonal allergen (trees, grasses, and/or ragweed) as confirmed by an allergic skin test within the past 24 months.

• have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart

Exclusion Criteria:

• have known contraindications or sensitivities to the use of the investigational product or any of its components

• have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or a diagnosis of dry eye)

• have had ocular surgical intervention within 3 months prior to Visit 1 or during the study and/or a history of refractive surgery within the past 6 months

• have a known history of retinal detachment, diabetic retinopathy, or active retinal disease

• have the presence of an active ocular infection (bacterial, viral or fungal) or positive history of an ocular herpetic infection at any visit

• use any of the disallowed medications* during the period indicated prior to Visit 1 and during the study

• have any significant illness (e.g. any autoimmune disease requiring therapy, severe cardiovascular disease [including arrhythmias] the investigator feels could be expected to interfere with the subject's health or with the study parameters and/or put the subject at any unnecessary risk (includes but is not limited to: poorly controlled hypertension or poorly controlled diabetes, a history of status asthmaticus, organ transplants, a known history of persistent moderate or severe asthma, or a known history of moderate to severe allergic asthmatic reactions to any of the study allergens;

• have planned surgery (ocular or systemic) during the trial period or within 30 days after;

• have used an investigational drug or medical device within 30 days of the study or be concurrently enrolled in another investigational product trial;

• be a female who is currently pregnant, planning a pregnancy, or lactating

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Drug:
• PR013 (0.045%)
PR013 topical Ophthalmic Drops (0.045%)
• PR013 (0.06%)
PR013 topical Ophthalmic Drops (0.06%)
• Vehicle
Vehicle

Locations

Country	Name	City	State
United States	Principal Investigator	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Realm Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ocular itching evaluated by the subject	The method of assessment for this outcome is the Ora Calibra(TM) Conjunctival Allergen Challenge Ocular Itching Scale	[Time Frame: Efficacy assessment period (Day 7 through Day 8)]
Primary	Conjunctival redness evaluated by the Investigator	Ora Calibra(TM) Ocular Hyperemia Scale	[Time Frame: Efficacy assessment period (Day 7 through Day 8)]